Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px
Document › Details

Roivant Sciences GmbH. (8/9/17). "Press Release: Roivant Sciences Raises $1.1 Billion in Equity Investment Led by SoftBank Vision Fund". Basel & London.

Organisations Organisation Roivant Sciences GmbH
  Group Roivant (Group)
  Organisation 2 SoftBank Vision Fund
  Group SoftBank (Group)
Products Product BIOTECH
  Product 2 private equity
Index terms Index term Roivant–SEVERAL: investment, 201708 financing round $1.1b led by SoftBank Vision Fund + incl Dexxon investor group
  Index term 2 Roivant–SoftBank: investment, 201708 financing round totalling $1.1b incl new + lead investor SoftBank Vision Fund
Persons Person Ramaswamy, Vivek (Roivant Sciences 201708 CEO + Founder)
  Person 2 Naheta, Akshay (SoftBank 201708 Managing Director of SoftBank Group International)
     


> Investment to fuel creation of new subsidiaries within and beyond biopharmaceutical development, including new technology-enabled ‘Vants’

> Financing includes existing shareholder participation


Roivant Sciences today announced a $1.1 billion equity investment led by the SoftBank Vision Fund. This investment, which includes existing shareholder participation, is intended to accelerate the launch of new subsidiaries within and beyond the biopharmaceutical industry.

Roivant focuses on developing and commercializing novel therapies through subsidiary ‘Vants’. These include Axovant (neurology), Myovant (women’s health and endocrine diseases), Dermavant (dermatology), Enzyvant (rare diseases), and Urovant (urology).

Datavant, a new technology-focused subsidiary, will be the first company in the Roivant family to operate outside of traditional biopharmaceutical development. Datavant aims to dissolve barriers between siloed healthcare datasets in order to unlock novel insights and reduce the time and cost of delivering innovative medicines to patients.

“We are pleased to welcome the SoftBank Vision Fund as a new investor in Roivant, and we are grateful for the continued support of our existing shareholders,” said Vivek Ramaswamy, Founder and CEO of Roivant. “I admire SoftBank’s long-term vision and I believe they will add significant strategic value to Roivant in the next phase of our growth.”

“Roivant has attracted world-class talent in its pursuit of developing and commercializing drugs that target large unmet medical needs,” said Akshay Naheta, Managing Director of SoftBank Group International. “We are impressed with the ambition and track record of the Roivant team and look forward to supporting them in the next step of their journey, as they look to effectively harness technology and leverage big data across all aspects of their business.”

“Roivant has come a very long way in a relatively short period of time,” said Dan Oren, President and CEO of Dexcel Pharma, a member of the Dexxon investor group which is both an initial investor in Roivant and a participant in this financing. “Since 2014 they have formed a diverse array of companies with many promising therapies in development. We supported Roivant at the very beginning and we continue to support them as they scale their operations and pursue new opportunities.”


About Roivant Sciences

Roivant is dedicated to transformative innovation in healthcare. Roivant focuses on realizing the full potential of promising biomedical research by developing and commercializing novel therapies across diverse therapeutic areas. We partner with innovative biopharmaceutical companies and academic institutions to ensure that important medicines are rapidly developed and delivered to patients.

We advance our drug pipelines through wholly- or majority-owned subsidiary companies, including Axovant (neurology), Myovant (women’s health and endocrine diseases), Dermavant (dermatology), Enzyvant (rare diseases), and Urovant (urology). Roivant also plans to launch new companies operating outside of traditional biopharmaceutical development. Roivant’s long-range mission is to reduce the time and cost of developing and delivering new medicines for patients. For more information, please visit roivant.com.


About the SoftBank Vision Fund

The SoftBank Vision Fund invests globally in the businesses and technologies that will enable the next stage of the Information Revolution, and make tomorrow’s world leading businesses possible.

The fund invests across all technology sectors and geographies, including computational biology, data-driven healthcare, and technology-enabled pharmaceutical businesses.

The Vision Fund will enable long-term, large-scale investments to fund growth and disruption in the technology sector.


Media Contact:

Paul Davis
Roivant Sciences, Inc.
paul.davis@roivant.com
Office: +1 (646) 495-5310

   
Record changed: 2017-08-18

Advertisement

Picture [LSF] Life-Sciences-France.com – The Business Web Portal 600x80px

More documents for Roivant (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2018 BTS San Francisco January 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Biotech Showcase 2018 BTS San Francisco January 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Biotech Showcase 2018 BTS San Francisco January 120x180px